By Chris Wack Crinetics Pharmaceuticals shares were up 15% at $46.60 after the company agreed to sell 8.3 million shares at a price of $42 a share to a.
Steven Cohen (Trades, Portfolio), through Point72 Asset Management, has recently made a notable adjustment in the firm's investment portfolio by reducing its stake in Crinetics Pharmaceuticals Inc (NASDAQ:CRNX). This trade has altered the firm's portfolio by a -0.09% impact, with CRNX now representing 0.36% of the total portfolio and 5.10% of the firm's holdings in the traded stock.
By Rob Curran Terns Pharmaceuticals named former Cleave Pharmaceuticals leader Amy Burroughs to its vacant chief executive role. Ms Burroughs, who previously.
Crinetics Pharmaceuticals (NASDAQ:CRNX – Get Free Report)‘s stock had its “overweight” rating restated by investment analysts at Cantor Fitzgerald in a note issued to investors on Friday, Benzinga reports. They presently have a $50.00 target price on the stock. Cantor Fitzgerald’s target price indicates a potential upside of 38.73% from the stock’s previous close. CRNX […]
Cantor Fitzgerald restated their overweight rating on shares of Crinetics Pharmaceuticals (NASDAQ:CRNX – Free Report) in a research report sent to investors on Friday, Benzinga reports. The brokerage currently has a $50.00 price target on the stock. Several other research firms also recently weighed in on CRNX. JPMorgan Chase & Co. restated an overweight rating […]